查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1541359

2024-2032 年淋巴瘤治疗市场报告（按类型、测试类型、药物和地区）

Lymphoma Treatment Market Report by Type, Test Type, Drug, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 146 Pages | 商品交期: 2-3个工作天内

价格

IMARC Group年全球淋巴瘤治疗市场规模达133亿美元。

淋巴瘤是指以淋巴系统中异常恶性细胞快速发展为特征的一类癌症。它通常以淋巴结、脾臟、胸腺和骨髓中的白血球 (WBC) 或淋巴细胞为目标，损害身体的免疫反应。结果，患者出现淋巴结肿胀、高烧、体重减轻、呼吸困难和疲倦。一些常用的淋巴瘤治疗方法包括放射线、化疗和单株抗体治疗、主动监测、骨髓移植和免疫疗法药物。这些疗法广泛用于治疗霍奇金淋巴瘤和非何杰金氏淋巴瘤。

全球非何杰金氏淋巴瘤盛行率的不断上升是推动市场成长的关键因素之一。此外，老年人口的增加也推动了市场的成长，老年人口更容易罹患此类疾病。与此一致的是，大众汽车对淋巴瘤可用诊断技术和治疗替代方案的认识不断提高，也为市场创造了积极的前景。医院和其他诊断中心正在使用创新的测试和影像技术，例如电脑断层扫描（CT）、磁振造影（MRI）和正子断层扫描（PET）扫描，以准确识别癌细胞并及时治疗。此外，各种技术进步，包括创新免疫检查点抑制剂的开发，可阻止蛋白质结合在一起并增强 T 细胞对抗癌细胞的反应强度，都有助于市场成长。其他因素，包括肿瘤学领域广泛的研发（R&D）活动，以及医疗保健基础设施的整体改善，预计将进一步推动市场发展。

本报告回答的关键问题：

  • 迄今为止，全球淋巴瘤治疗市场表现如何，未来几年将如何表现？
  • COVID-19 对全球淋巴瘤治疗市场有何影响？
  • 主要区域市场有哪些？
  • 依类型划分市场是怎么样的？
  • 根据测试类型，市场的细分是什么？
  • 基于药物的市场区隔是什么？
  • 产业价值链的各个阶段是什么？
  • 该行业的关键驱动因素和挑战是什么？
  • 全球淋巴瘤治疗市场的结构如何？
  • 产业竞争程度如何？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 数据来源
    • 主要来源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球淋巴瘤治疗市场

  • 市场概况
  • 市场表现
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：按类型

  • 霍奇金淋巴瘤
    • 市场趋势
    • 市场预测
  • 非何杰金氏淋巴瘤
    • 市场趋势
    • 市场预测

第 7 章：市场区隔：按测试类型

  • 化疗
    • 市场趋势
    • 市场预测
  • 放射治疗
    • 市场趋势
    • 市场预测
  • 免疫疗法
    • 市场趋势
    • 市场预测
  • 标靶治疗
    • 市场趋势
    • 市场预测
  • 生物疗法
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 8 章：市场区隔：依药品分类

  • 阿德塞特里斯
    • 市场趋势
    • 市场预测
  • 利妥昔单抗
    • 市场趋势
    • 市场预测
  • 奥狄沃
    • 市场趋势
    • 市场预测
  • 伊布维卡
    • 市场趋势
    • 市场预测
  • 可瑞达
    • 市场趋势
    • 市场预测
  • 来那度胺
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 9 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场趋势
    • 市场细分：按国家/地区
    • 市场预测

第 10 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 11 章：价值链分析

第 12 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 13 章：价格分析

第14章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Abbott Laboratories
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd.
    • Johnson & Johnson Services, Inc.
    • Merck & Co. Inc.
    • Novartis International AG
    • Spectrum Pharmaceuticals, Inc.
    • Takeda Pharmaceutical Company Ltd.
    • Teva Pharmaceutical Industries Ltd.
Product Code: SR112024A3385

The global lymphoma treatment market size reached US$ 13.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 26.0 Billion by 2032, exhibiting a growth rate (CAGR) of 7.5% during 2024-2032.

Lymphoma refers to a type of cancer characterized by the rapid development of abnormal malignant cells in the lymphatic system. It usually targets the white blood cells (WBCs), or lymphocytes, in lymph nodes, spleen, thymus and bone marrow and impairs the immune response of the body. As a result, the patient develops swelling in the lymph nodes, high fever, weight loss, dyspnea and fatigue. Some of the commonly used lymphoma therapeutics include radiation, chemo and monoclonal antibody therapy, active surveillance, bone marrow transplant and immunotherapy drugs. These therapeutics are widely used for the treatment of both Hodgkin and non-Hodgkin lymphoma.

The increasing prevalence of non-Hodgkin lymphoma across the globe represents one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such ailments, is also driving the market growth. In line with this, the increasing awareness among the masses regarding the available diagnostic technologies and treatment alternatives for lymphoma is also creating a positive outlook for the market. Hospitals and other diagnostic centers are using innovative tests and imaging technologies, such as computed tomography (CT), Magnetic Resonance Imaging (MRI) and positron emission tomography (PET) scans, for accurate identification of the cancer cells and timely treatment. Additionally, various technological advancements, including the development of innovative immune checkpoint inhibitors, which block proteins from binding together and increase the response strength of T-cells against cancer cells, are contributing to the market growth. Other factors, including extensive research and development (R&D) activities in the field of oncology, along with overall improvements in the healthcare infrastructure, are anticipated to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global lymphoma treatment market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, test type and drug.

Breakup by Type:

Hodgkin Lymphoma

Non-Hodgkin Lymphoma

Breakup by Test Type:

Chemotherapy

Radiation Therapy

Immunotherapy

Targeted Therapy

Biologic Therapy

Others

Breakup by Drug:

Adcetris

Rituxan

Opdivo

Imbruvica

Keytruda

Revlimid

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis International AG, Spectrum Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report:

  • How has the global lymphoma treatment market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global lymphoma treatment market?
  • What are the key regional markets?
  • What is the breakup of the market based on the type?
  • What is the breakup of the market based on the test type?
  • What is the breakup of the market based on the drug?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global lymphoma treatment market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Lymphoma Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Hodgkin Lymphoma
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Non-Hodgkin Lymphoma
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Test Type

  • 7.1 Chemotherapy
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Radiation Therapy
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Immunotherapy
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Targeted Therapy
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Biologic Therapy
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Others
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast

8 Market Breakup by Drug

  • 8.1 Adcetris
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Rituxan
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Opdivo
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Imbruvica
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Keytruda
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Revlimid
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast
  • 8.7 Others
    • 8.7.1 Market Trends
    • 8.7.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbott Laboratories
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Bristol-Myers Squibb Company
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Eli Lilly and Company
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 F. Hoffmann-La Roche Ltd.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 SWOT Analysis
    • 14.3.5 Johnson & Johnson Services, Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Merck & Co. Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Novartis International AG
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Spectrum Pharmaceuticals, Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Takeda Pharmaceutical Company Ltd.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Teva Pharmaceutical Industries Ltd.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Lymphoma Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Lymphoma Treatment Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Lymphoma Treatment Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Lymphoma Treatment Market: Breakup by Type (in %), 2023
  • Figure 5: Global: Lymphoma Treatment Market: Breakup by Test Type (in %), 2023
  • Figure 6: Global: Lymphoma Treatment Market: Breakup by Drug (in %), 2023
  • Figure 7: Global: Lymphoma Treatment Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Lymphoma Treatment (Hodgkin Lymphoma) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Lymphoma Treatment (Hodgkin Lymphoma) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Lymphoma Treatment (Non-Hodgkin Lymphoma) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Lymphoma Treatment (Non-Hodgkin Lymphoma) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Lymphoma Treatment (Chemotherapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Lymphoma Treatment (Chemotherapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Lymphoma Treatment (Radiation Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Lymphoma Treatment (Radiation Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Lymphoma Treatment (Immunotherapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Lymphoma Treatment (Immunotherapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Lymphoma Treatment (Targeted Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Lymphoma Treatment (Targeted Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Lymphoma Treatment (Biologic Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Lymphoma Treatment (Biologic Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Lymphoma Treatment (Other Test Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Lymphoma Treatment (Other Test Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Lymphoma Treatment (Adcetris) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Lymphoma Treatment (Adcetris) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Lymphoma Treatment (Rituxan) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Lymphoma Treatment (Rituxan) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Lymphoma Treatment (Opdivo) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Lymphoma Treatment (Opdivo) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Global: Lymphoma Treatment (Imbruvica) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Global: Lymphoma Treatment (Imbruvica) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Global: Lymphoma Treatment (Keytruda) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Global: Lymphoma Treatment (Keytruda) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Global: Lymphoma Treatment (Revlimid) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Global: Lymphoma Treatment (Revlimid) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Global: Lymphoma Treatment (Other Drugs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Global: Lymphoma Treatment (Other Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: North America: Lymphoma Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: North America: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: United States: Lymphoma Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: United States: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Canada: Lymphoma Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Canada: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Asia-Pacific: Lymphoma Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Asia-Pacific: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: China: Lymphoma Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: China: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Japan: Lymphoma Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Japan: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: India: Lymphoma Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: India: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: South Korea: Lymphoma Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: South Korea: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Australia: Lymphoma Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Australia: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Indonesia: Lymphoma Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Indonesia: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Others: Lymphoma Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Others: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Europe: Lymphoma Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Europe: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Germany: Lymphoma Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Germany: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: France: Lymphoma Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: France: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: United Kingdom: Lymphoma Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: United Kingdom: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Italy: Lymphoma Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Italy: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Spain: Lymphoma Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Spain: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Russia: Lymphoma Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Russia: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Others: Lymphoma Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Others: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Latin America: Lymphoma Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Latin America: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: Brazil: Lymphoma Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 79: Brazil: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 80: Mexico: Lymphoma Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 81: Mexico: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 82: Others: Lymphoma Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 83: Others: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 84: Middle East and Africa: Lymphoma Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 85: Middle East and Africa: Lymphoma Treatment Market: Breakup by Country (in %), 2023
  • Figure 86: Middle East and Africa: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 87: Global: Lymphoma Treatment Industry: SWOT Analysis
  • Figure 88: Global: Lymphoma Treatment Industry: Value Chain Analysis
  • Figure 89: Global: Lymphoma Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Lymphoma Treatment Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Lymphoma Treatment Market Forecast: Breakup by Type (in Million US$), 2024-2032
  • Table 3: Global: Lymphoma Treatment Market Forecast: Breakup by Test Type (in Million US$), 2024-2032
  • Table 4: Global: Lymphoma Treatment Market Forecast: Breakup by Drug (in Million US$), 2024-2032
  • Table 5: Global: Lymphoma Treatment Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Lymphoma Treatment Market: Competitive Structure
  • Table 7: Global: Lymphoma Treatment Market: Key Players